Wayne State University, Department of Medicine, University Health Center, Suite 5C, 4201 St. Antoine, Detroit, MI 48201, USA.
Expert Opin Pharmacother. 2010 Mar;11(4):615-25. doi: 10.1517/14656561003598893.
Infections caused by Gram-positive organisms have increased in frequency and severity. Daptomycin offers a therapeutic option in an era of increasing resistance.
Literature from 1986 to present was reviewed for pharmacological, preclinical and clinical studies on daptomycin.
The pharmacological properties, resistance mechanisms and clinical applications of daptomycin are discussed. Recommendations are offered on the use of this agent for the treatment of resistant Gram-positive infections.
Daptomycin is a reliable agent for the treatment of Gram-positive infections. It has been shown to be effective in bacteremia and endocarditis, as well as in soft-tissue infections caused by Gram-positive organisms. Its role in the treatment of bone and joint infections is not well-defined. Resistance is currently uncommon in clinical isolates. However, emergence of resistance during therapy is a concern. This may be prevented by use of higher doses.
由革兰氏阳性菌引起的感染的频率和严重程度都有所增加。达托霉素在耐药性日益增加的时代提供了一种治疗选择。
对 1986 年至今的文献进行了回顾,以获取关于达托霉素的药理学、临床前和临床研究。
讨论了达托霉素的药理学特性、耐药机制和临床应用。就该药物治疗耐药性革兰氏阳性感染的应用提出了建议。
达托霉素是治疗革兰氏阳性感染的可靠药物。已证明其在菌血症和心内膜炎以及由革兰氏阳性菌引起的软组织感染中有效。其在治疗骨和关节感染中的作用尚未明确。目前,临床分离株中耐药性少见。然而,在治疗过程中出现耐药性是令人担忧的。这可以通过使用更高的剂量来预防。